These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 1835276)

  • 21. Lack of effect of lovastatin on restenosis after coronary angioplasty. Lovastatin Restenosis Trial Study Group.
    Weintraub WS; Boccuzzi SJ; Klein JL; Kosinski AS; King SB; Ivanhoe R; Cedarholm JC; Stillabower ME; Talley JD; DeMaio SJ
    N Engl J Med; 1994 Nov; 331(20):1331-7. PubMed ID: 7935702
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Morphologic changes during follow-up after successful percutaneous transluminal coronary balloon angioplasty: quantitative angiographic analysis in 778 lesions--further evidence for the restenosis paradox. MERCATOR Study Group (Multicenter European Research trial with Cilazapril after Angioplasty to prevent Transluminal Coronary Obstruction and Restenosis).
    Hermans WR; Foley DP; Rensing BJ; Serruys PW
    Am Heart J; 1994 Mar; 127(3):483-94. PubMed ID: 8122593
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of antiplatelet agents in modifying the extent of restenosis following percutaneous transluminal coronary angioplasty.
    Schwartz L; Lesperance J; Bourassa MG; Eastwood C; Kazim F; Arafah M; Ganassin L
    Am Heart J; 1990 Feb; 119(2 Pt 1):232-6. PubMed ID: 2405609
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized, double-blind, placebo-controlled trial of abciximab for prevention of in-stent restenosis in diabetic patients after coronary stenting: results of the ASIAD (Abciximab in Stenting Inhibits restenosis Among Diabetics) Trial.
    Chen WH; Kaul U; Leung SK; Lau YK; Tan HC; Leung AW; Lee MK; Li SK; Ng W; Lee PY; Lam KF; Tse HF; Lau CP
    J Invasive Cardiol; 2005 Oct; 17(10):534-8. PubMed ID: 16204748
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of low-dose aspirin on restenosis after coronary angioplasty.
    Taylor RR; Gibbons FA; Cope GD; Cumpston GN; Mews GC; Luke P
    Am J Cardiol; 1991 Oct; 68(9):874-8. PubMed ID: 1927946
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of recombinant hirudin (CGP 39,393/TMREVASC) in the prevention of restenosis after percutaneous transluminal coronary angioplasty. Rationale and design of the HELVETICA trial, a multicentre randomized double blind heparin controlled study.
    Herrman JP; Simon R; Umans VA; Peerboom PF; Keane D; Rijnierse JJ; Bach D; Kobi P; Kerry R; Close P
    Eur Heart J; 1995 Nov; 16 Suppl L():56-62. PubMed ID: 8869020
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of the direct nitric oxide donors linsidomine and molsidomine on angiographic restenosis after coronary balloon angioplasty. The ACCORD Study. Angioplastic Coronaire Corvasal Diltiazem.
    Lablanche JM; Grollier G; Lusson JR; Bassand JP; Drobinski G; Bertrand B; Battaglia S; Desveaux B; Juillière Y; Juliard JM; Metzger JP; Coste P; Quiret JC; Dubois-Randé JL; Crochet PD; Letac B; Boschat J; Virot P; Finet G; Le Breton H; Livarek B; Leclercq F; Béard T; Giraud T; Bertrand ME
    Circulation; 1997 Jan; 95(1):83-9. PubMed ID: 8994421
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Beneficial effects of combined thromboxane synthase inhibition/receptor blockade with CGS 22652 in a canine model of coronary thrombosis.
    Olson RW; Dotson R; Mathis J; Cohen DS; Webb RL
    Eur J Pharmacol; 1993 May; 236(1):75-87. PubMed ID: 8319746
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of diltiazem on complications and restenosis after coronary angioplasty.
    O'Keefe JH; Giorgi LV; Hartzler GO; Good TH; Ligon RW; Webb DL; McCallister BD
    Am J Cardiol; 1991 Feb; 67(5):373-6. PubMed ID: 1994661
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. Multivitamins and Probucol Study Group.
    Tardif JC; Cöté G; Lespérance J; Bourassa M; Lambert J; Doucet S; Bilodeau L; Nattel S; de Guise P
    N Engl J Med; 1997 Aug; 337(6):365-72. PubMed ID: 9241125
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low molecular weight heparin in prevention of restenosis after angioplasty. Results of Enoxaparin Restenosis (ERA) Trial.
    Faxon DP; Spiro TE; Minor S; Coté G; Douglas J; Gottlieb R; Califf R; Dorosti K; Topol E; Gordon JB
    Circulation; 1994 Aug; 90(2):908-14. PubMed ID: 8044962
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of nadroparin, a low-molecular-weight heparin, on clinical and angiographic restenosis after coronary balloon angioplasty: the FACT study. Fraxiparine Angioplastie Coronaire Transluminale.
    Lablanche JM; McFadden EP; Meneveau N; Lusson JR; Bertrand B; Metzger JP; Legrand V; Grollier G; Macaya C; de Bruyne B; Vahanian A; Grentzinger A; Masquet C; Wolf JE; Tobelem G; Fontecave S; Vacheron A; d'Azemar P; Bertrand ME
    Circulation; 1997 Nov; 96(10):3396-402. PubMed ID: 9396433
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Review of antiplatelet drug use in preventing restenosis following percutaneous transluminal coronary angioplasty.
    Cox JL; Gotlieb AI
    Can J Cardiol; 1988 May; 4(4):201-10. PubMed ID: 2456140
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Luminal narrowing after percutaneous transluminal coronary angioplasty. A study of clinical, procedural, and lesional factors related to long-term angiographic outcome. Coronary Artery Restenosis Prevention on Repeated Thromboxane Antagonism (CARPORT) Study Group.
    Rensing BJ; Hermans WR; Vos J; Tijssen JG; Rutch W; Danchin N; Heyndrickx GR; Mast EG; Wijns W; Serruys PW
    Circulation; 1993 Sep; 88(3):975-85. PubMed ID: 8353925
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty.
    Schwartz L; Bourassa MG; Lespérance J; Aldridge HE; Kazim F; Salvatori VA; Henderson M; Bonan R; David PR
    N Engl J Med; 1988 Jun; 318(26):1714-9. PubMed ID: 2967433
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A paclitaxel-eluting stent for the prevention of coronary restenosis.
    Park SJ; Shim WH; Ho DS; Raizner AE; Park SW; Hong MK; Lee CW; Choi D; Jang Y; Lam R; Weissman NJ; Mintz GS
    N Engl J Med; 2003 Apr; 348(16):1537-45. PubMed ID: 12700373
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thromboxane synthase inhibitors and receptor antagonists.
    Vermylen J; Deckmyn H
    Cardiovasc Drugs Ther; 1992 Feb; 6(1):29-33. PubMed ID: 1533533
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators.
    Lincoff AM; Califf RM; Moliterno DJ; Ellis SG; Ducas J; Kramer JH; Kleiman NS; Cohen EA; Booth JE; Sapp SK; Cabot CF; Topol EJ
    N Engl J Med; 1999 Jul; 341(5):319-27. PubMed ID: 10423466
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pravastatin reduces restenosis two years after percutaneous transluminal coronary angioplasty (REGRESS trial).
    Mulder HJ; Bal ET; Jukema JW; Zwinderman AH; Schalij MJ; van Boven AJ; Bruschke AV
    Am J Cardiol; 2000 Oct; 86(7):742-6. PubMed ID: 11018193
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of short-term prostacyclin administration on restenosis after percutaneous transluminal coronary angioplasty.
    Knudtson ML; Flintoft VF; Roth DL; Hansen JL; Duff HJ
    J Am Coll Cardiol; 1990 Mar; 15(3):691-7. PubMed ID: 2105988
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.